Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emactuzumab - SynOx Therapeutics

Next Previous
Drug Profile

Emactuzumab - SynOx Therapeutics

Alternative Names: RG-7155; RO-5509554

Latest Information Update: 24 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Roche; SynOx Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumour of tendon sheath
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Giant cell tumour of tendon sheath
  • Discontinued Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 13 Apr 2026 The US FDA plans to file BLA for emactuzumab for treatment of Giant cell tumour of tendon sheath in second half of 2026
  • 13 Apr 2026 Adverse events and efficacy data from a phase III trial in Giant cell tumour of tendon sheath presented by SynOx Therapeutics
  • 13 Apr 2026 SynOx Therapeutics announces intention to submit MAA to European Union for Giant cell tumour of tendon sheath

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top